文献速递消化系统肿瘤

基线癌胚抗原对转移性结直肠癌一线FOLFIRI联合西妥昔单抗或贝伐珠单抗治疗的相关性(FIRE-3试验)

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
PubMed 文献 · Eur J Cancer · 2018-11-27

FIRE-3研究分析RAS野生型转移性结直肠癌患者基线癌胚抗原(CEA)与靶向治疗预后的关系。高CEA(>10 ng/ml)在贝伐珠单抗组与较短总生存相关(HR=1.50,P=0.036),西妥昔单抗组无显著差异(HR=1.07,P=0.74)。高CEA患者中西妥昔单抗较贝伐珠单抗总生存获益更大(HR=0.56,P<0.001),客观缓解率亦显著更优(OR=2.21,P=0.006)。

要点

  • 高CEA(>10 ng/ml)在FOLFIRI/Bev组与较短OS相关(HR=1.50,P=0.036),FOLFIRI/Cet组无显著差异(HR=1.07,P=0.74)。
  • 高CEA患者中FOLFIRI/Cet较FOLFIRI/Bev的OS获益(HR=0.56,P<0.001)大于低CEA患者(HR=0.78,P=0.30)。
  • 高CEA患者中FOLFIRI/Cet的客观缓解率显著优于FOLFIRI/Bev(OR=2.21,P=0.006),低CEA患者无显著差异(OR=0.90,P=0.85)。

核心结论

  • 在接受一线FOLFIRI/Cet或FOLFIRI/Bev的RAS-WT mCRC患者中,高CEA在贝伐珠单抗组与较差生存相关,而在西妥昔单抗组未见此关联。
  • 按治疗组比较OS和客观缓解率显示,高CEA患者中西妥昔单抗大幅优于贝伐珠单抗,而低CEA患者中该效应明显较小且失去统计学显著性。

研究设计与样本

  • FIRE-3是一项随机III期研究,评估一线FOLFIRI联合西妥昔单抗(FOLFIRI/Cet)对比FOLFIRI联合贝伐珠单抗(FOLFIRI/Bev)在RAS-WT(KRAS和NRAS第2-4外显子野生型)mCRC患者中的疗效。
  • 400例患者中356例(89.0%)可评估CEA。

主要发现

  • 高CEA(>10 ng/ml;N=237)对比低CEA(≤10 ng/ml;N=119)在FOLFIRI/Bev组与较短OS相关(HR=1.50;P=0.036)。
  • FOLFIRI/Cet组高CEA与低CEA之间未观察到显著OS差异(HR=1.07;P=0.74)。
  • 高CEA患者中FOLFIRI/Cet对比FOLFIRI/Bev显示更大的OS获益(HR=0.56;P<0.001),低CEA患者中为HR=0.78(P=0.30)。
  • 高CEA患者中FOLFIRI/Cet的客观缓解率显著更优(OR=2.21;P=0.006),低CEA患者中为OR=0.90(P=0.85)。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Increased baseline carcinoembryonic antigen (CEA) serum level is associated with inferior overall survival (OS) in metastatic colorectal cancer (mCRC). However, limited data exist on its predictive relevance for targeted therapies. Therefore, we analysed its relevance in FIRE-3, a randomised phase III study. EXPERIMENTAL DESIGN: FIRE-3 evaluated first-line FOLFIRI plus cetuximab (FOLFIRI/Cet) versus FOLFIRI plus bevacizumab (FOLFIRI/Bev) in mCRC patients with RAS-WT tumour (i.e. wild-type in KRAS and NRAS exons 2-4). Herein, the impact of CEA on patient outcome was investigated. RESULTS: Of 400 patients, 356 (89.0%) were evaluable for CEA. High CEA (>10 ng/ml; N = 237) compared to low CEA (≤10 ng/ml; N = 119) was associated with shorter OS in the FOLFIRI/Bev arm (hazard ratio [HR] = 1.50; P = 0.036), while no significant OS difference was observed in the FOLFIRI/Cet arm (HR = 1.07; P = 0.74). In patients with high CEA, FOLFIRI/Cet compared to FOLFIRI/Bev showed a greater OS benefit (HR = 0.56; P < 0.001) than in patients with low CEA (HR = 0.78; P = 0.30). Furthermore, FOLFIRI/Cet exhibited significantly superior objective response rate in patients with high CEA (odds ratio = 2.21; P = 0.006) in contrast to patients with low CEA (odds ratio = 0.90; P = 0.85). CONCLUSION: In patients with RAS-WT mCRC receiving first-line chemotherapy with FOLFIRI/Cet versus FOLFIRI/Bev, elevated CEA was associated with inferior survival in the bevacizumab arm, while this was not the case when cetuximab was applied. Comparison of OS and objective response rate according to treatment arms indicated that cetuximab was greatly superior to bevacizumab in patients with elevated CEA, while this effect was markedly lower and lost statistical significance in patients with low CEA.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Holch JW, Ricard I, Stintzing S, et al. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Eur J Cancer. 2018. PMID: 30496943. doi:10.1016/j.ejca.2018.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。